SPRYCEL vs TABRECTA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 17, 2026·How we rate

Possible drug interaction. SPRYCEL and TABRECTA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	SPRYCEL	TABRECTA
Rating	72/100	70/100
Pharmacy pays	~$839.19 /30	—
Type	RX	RX
Active ingredient	DASATINIB	CAPMATINIB HYDROCHLORIDE
Manufacturer	Bristol Myers Squibb	Novartis
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Lymphoid Leukemia, Myeloid Leukemia	Non-Small-Cell Lung Carcinoma

sprycel tabrecta

Rating

72/100

70/100

Pharmacy pays

~$839.19 /30

—

Type

Active ingredient

DASATINIB

CAPMATINIB HYDROCHLORIDE

Manufacturer

Bristol Myers Squibb

Novartis

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Lymphoid Leukemia, Myeloid Leukemia

Non-Small-Cell Lung Carcinoma

Frequently asked questions

Which is better-rated, Sprycel or Tabrecta?

By our independent rating, Sprycel scores higher — 3.6 vs 3.5 out of 5 for Tabrecta. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Sprycel and Tabrecta?

Sprycel contains Dasatinib, while Tabrecta contains Capmatinib Hydrochloride — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.